Format

Send to

Choose Destination
J Cell Physiol. 2017 Jun;232(6):1458-1466. doi: 10.1002/jcp.25648. Epub 2016 Nov 30.

PPARα Antagonist AA452 Triggers Metabolic Reprogramming and Increases Sensitivity to Radiation Therapy in Human Glioblastoma Primary Cells.

Author information

1
Depatment of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
2
Department of Pharmacy, G. d'Annunzio University, Chieti, Italy.
3
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
4
Institute of Endocrinology and Experimental Oncology (IEOS), CNR, Naples, Italy.
5
Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, Pennsylvania.
6
Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
7
Gran Sasso National Laboratory (LNGS), National Institute for Nuclear Physics (INFN), Assergi, Italy.

Abstract

Glioblastoma (GB) is the most common cancer in the brain and with an increasing incidence. Despite major advances in the field, there is no curative therapy for GB to date. Many solid tumors, including GB, experienced metabolic reprogramming in order to sustain uncontrolled proliferation, hypoxic conditions, and angiogenesis. PPARs, member of the steroid hormone receptor superfamily, are particularly involved in the control of energetic metabolism, particularly lipid metabolism, which has been reported deregulated in gliomas. PPARα was previously indicated by us as a potential therapeutic target for this neoplasm, due to the malignancy grade dependency of its expression, being particularly abundant in GB. In this work, we used a new PPARα antagonist on patient-derived GB primary cells, with particular focus on the effects on lipid metabolism and response to radiotherapy. The results obtained demonstrated that blocking PPARα results in cell death induction, increase of radiosensitivity, and decrease of migration. Therefore, AA452 is proposed as a new adjuvant for the gold standard therapies for GB, opening the possibility for preclinical and clinical trials for this class of compounds. J. Cell. Physiol. 232: 1458-1466, 2017.

PMID:
27736000
DOI:
10.1002/jcp.25648
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center